DNTH logo

DNTH Dianthus Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$84.83
+0.85 (+1.01%)

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets…

Market Cap: $4.78Bdianthustx.com

Price

No data yet.

Social Signal Score

61
5d
—
30d
63
2 mentions
—
60d
62
4 mentions
—
90d
58
9 mentions
—
rss: 3 · news: 6

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 1Buy 10Hold 0Sell 0Strong Sell 0
Avg price target$136.5+60.9%
Low $122Median $133High $158
Current Consensus

Revenue

$1.21M
$0.00$724.0K$1.45M$2.17M
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-3.68
$-4.63–$-3.11
7 analysts
FY2026
$-3.53
$-3.68–$-3.37
10 analysts
FY2027
$-4.38
$-5.27–$-3.89
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Marino Garcia
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
0.08
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
83.06
dianthustx.com